Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of “Hold” by Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been given a consensus recommendation of “Hold” by the twenty-four research firms that are covering the stock, MarketBeat reports. Six research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $24.8095.

Several analysts recently commented on SRPT shares. Wedbush increased their price objective on shares of Sarepta Therapeutics from $29.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 26th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Sarepta Therapeutics from $12.00 to $14.00 and gave the stock a “sell” rating in a report on Thursday, March 26th. HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a research note on Thursday, April 16th. Royal Bank Of Canada increased their price target on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a report on Tuesday, April 7th. Finally, Weiss Ratings downgraded shares of Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, June 29th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Kestra Advisory Services LLC purchased a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at $25,000. iSAM Funds UK Ltd purchased a new position in Sarepta Therapeutics in the 3rd quarter worth about $25,000. Ancora Advisors LLC lifted its stake in Sarepta Therapeutics by 200.0% during the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 1,000 shares during the period. Allworth Financial LP lifted its stake in Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,721 shares during the period. Finally, Larson Financial Group LLC boosted its holdings in shares of Sarepta Therapeutics by 82.5% during the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 851 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $19.28 on Friday. Sarepta Therapeutics has a 12 month low of $10.41 and a 12 month high of $25.32. The company has a market capitalization of $2.04 billion, a price-to-earnings ratio of -20.08, a price-to-earnings-growth ratio of 0.20 and a beta of 0.21. The business’s fifty day simple moving average is $17.85 and its two-hundred day simple moving average is $19.34. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, beating the consensus estimate of $0.98 by $2.18. The firm had revenue of $730.80 million during the quarter, compared to the consensus estimate of $474.15 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The company’s revenue was down 1.9% on a year-over-year basis. During the same period last year, the company earned ($3.42) earnings per share. As a group, equities analysts predict that Sarepta Therapeutics will post 3.95 earnings per share for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.